India is the 'Pharmacy of the World' yet struggles with API import dependence. Examine.

Q. India is the 'Pharmacy of the World' yet struggles with API import dependence. Examine. (15 marks, 250-350 words)

India is the third-largest drug producer by volume, supplying about 20% of global generics and 60% of the world's vaccines [2]. Yet this formulation strength rests on imported bulk drugs — a paradox of scale without depth in the value chain.

Basis of the 'Pharmacy of the World' claim - Global supply role: exports to 200+ countries; dominant share of WHO's vaccine demand for DPT, BCG and measles [2]. - Domestic affordability: Jan Aushadhi Kendras grew from 84 (2014) to 19,200+ (2026), saving citizens ₹40,000 crore+ [1]; generics priced 50–90% below branded equivalents [4]. - Manufacturing scale-up: PLI for pharma and medical devices has drawn cumulative investment of ₹42,694 crore, sales of ₹3.43 lakh crore and 1.13 lakh+ jobs [1].

The API dependence problem - Import reliance: India imports a large share of critical bulk drugs, KSMs and drug intermediates, with sourcing heavily concentrated in China [3]. - Cause — economics, not capability: imports persist "largely for economic considerations" [3] — cost disadvantage in fermentation-based APIs, absence of scale, and high utility and common-infrastructure costs. - Strategic vulnerability: COVID-19 supply shocks showed how a single-source disruption can halt essential-medicine production. - Value trap: third by volume but only 14th by value [2] — low-margin generics with limited innovation depth.

Corrective architecture - PLI for Bulk Drugs (₹6,940 crore, 2020) — actual investment reached ₹4,570 crore by March 2025, exceeding commitments [3]. - Bulk Drug Parks: three sanctioned in Andhra Pradesh, Gujarat and Himachal Pradesh, with grant-in-aid up to ₹1,000 crore each for shared infrastructure [3]. - PRIP (₹5,000 crore) shifts the sector from cost-based to innovation-based growth [2].

India's dependence is a structural cost gap rather than a technological one, and is therefore correctable. Sustaining park utilisation, green-chemistry process innovation and predictable fiscal support beyond scheme timelines can convert volume leadership into value leadership — securing both Atmanirbharta and the affordable-access promise underlying SDG-3.

(~330 words)

Sources: 1. 12 Years of Transformative Growth in Pharmaceuticals Sector, PIB (17 June 2026) — Jan Aushadhi Kendra growth, ₹40,000 crore savings, PLI investment/sales/employment figures 2. India's Pharmaceuticals in Global Healthcare, PIB — 20% of global generics, 60% vaccine share, volume-vs-value rank, PRIP outlay 3. Bulk Drug Park Scheme, PIB — API/KSM import dependence and its economic causes, Bulk Drug Parks (AP/Gujarat/HP, ₹1,000 crore each), Bulk Drugs PLI outlay and realised investment 4. Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), PIB — generic medicines priced 50–90% below branded equivalents